文献速递主动脉疾病

经腔静脉栓塞治疗EVAR后II型内漏:肾下、近肾及IV型胸腹主动脉瘤的结局

Transcaval embolization for type II endoleak after endovascular aortic repair of infrarenal, juxtarenal, and type IV thoracoabdominal aortic aneurysm.
PubMed 文献 · J Vasc Surg · 2021-03-01

本研究回顾性分析了24例患者共25次经腔静脉栓塞(TCE)手术,用于治疗肾下EVAR及开窗/分支EVAR(F/BEVAR)后因II型内漏导致的瘤囊增大(≥5mm)。技术成功率96.0%,院内并发症及30天死亡率为0%,中位随访23.1个月,12个月免于II型内漏相关再干预率为84.6%。结论认为TCE是伴有瘤囊增大的II型内漏可接受的治疗选择。

要点

  • TCE技术成功率达96.0%,院内并发症和30天死亡率为0%。
  • 12个月免于II型内漏相关再干预率为84.6%。
  • 非选择性与选择性TCE后再干预率分别为16.7%和20%。

核心结论

  • TCE是伴有瘤囊增大的II型内漏可接受的治疗选择。
  • TCE可用于肾下腹主动脉瘤EVAR后及近肾腹主动脉瘤和IV型胸腹主动脉瘤F/BEVAR后的II型内漏。

研究设计与样本

  • 回顾性单中心队列研究,纳入2015年8月至2019年8月间所有连续TCE手术。
  • 共纳入24例患者的25次TCE手术,男性占95.8%。
  • TCE指征为肾下EVAR或近肾/IV型胸腹主动脉瘤F/BEVAR后因II型内漏导致瘤囊增大≥5mm。

主要发现

  • 技术成功率为96.0%(24/25)。
  • 选择性和非选择性TCE分别在48%的患者中实施。
  • 院内并发症和30天死亡率均为0%。
  • 中位随访23.1个月(IQR 10.9-40.1个月),12个月免于II型内漏相关再干预率为84.6%。
  • 非选择性TCE后再干预率为16.7%,选择性TCE后为20%;EVAR后为12.5%,F/BEVAR后为33.3%。

临床怎么用

  • 对于EVAR或F/BEVAR后因II型内漏导致瘤囊增大≥5mm的患者,可考虑行TCE。
  • TCE术后需随访监测内漏相关再干预。

局限性

  • 回顾性单中心设计,样本量较小(24例患者,25次手术)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to determine the outcomes of transcaval embolization (TCE) for type II endoleak after infrarenal endovascular aortic repair (EVAR) and fenestrated/branched EVAR (F/BEVAR). METHODS: A retrospective single-center cohort study of all consecutive TCE procedures between August 2015 and August 2019 was performed to investigate technical success, in-hospital morbidity, and 30-day mortality as well as clinical success during follow-up. The indication for TCE was an aneurysm sac growth of 5 mm or more owing to a type II endoleak after EVAR for infrarenal or F/BEVAR for juxtarenal and type IV thoracoabdominal aortic aneurysm. RESULTS: A total 25 TCE procedures in 24 patients (95.8% male) were included. Technical success was 96.0% (24/25); selective and nonselective TCE were performed in 48% of patients. The in-hospital morbidity and 30-day mortality were 0%. The median follow-up was 23.1 months (interquartile range, 10.9-40.1 months). Freedom from type II endoleak-related reintervention was 84.6% at 12 months. Comparing clinical success after TCE, reintervention was necessary in 16.7% of patients after nonselective and 20% of patients after selective TCE. Regarding TCE after EVAR vs F/BEVAR, reintervention was performed in 12.5% of EVAR and 33.3% of F/BEVAR patients during follow-up. CONCLUSIONS: TCE is an acceptable treatment alternative for type II endoleak with aneurysm sac enlargement and can be used after EVAR for infrarenal abdominal aortic aneurysms and F/BEVAR for juxtarenal abdominal aortic aneurysms and type IV thoracoabdominal aortic aneurysms.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Heidemann F, Rohlffs F, Tsilimparis N, et al. Transcaval embolization for type II endoleak after endovascular aortic repair of infrarenal, juxtarenal, and type IV thoracoabdominal aortic aneurysm. J Vasc Surg. 2021. PMID: 33348001. doi:10.1016/j.jvs.2020.12.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。